{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T09:23:15Z","timestamp":1777195395517,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study aimed to clarify the effect of early glucocorticoid (GC) application on achieving minimal manifestation (MM) status or better in the treatment of myasthenia gravis (MG) in the early clinical phase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was performed using data from 336 patients with MG who received GC therapy from January 2015 to September 2022 in the Zhengzhou University Henan Institute of Medical and Pharmaceutical Sciences Myasthenia Gravis Biobank (ZMB). Patients were divided into two groups: the early mono-GC group (treated with GC within 6 months of MG onset) and the delayed mono-GC group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Kaplan\u2013Meier analysis showed that the early mono-GC group achieved MM status earlier and more frequently than the delayed mono-GC group (log-rank test, <jats:italic>p<\/jats:italic> = 0.0082; hazard ratio [HR], 1.66; <jats:italic>p<\/jats:italic> = 0.011). The early mono-GC group had a lower maintenance oral GC dose than the delayed mono-GC group. In multivariate Cox regression analysis, early mono-GC (HR, 1.50; <jats:italic>p<\/jats:italic> = 0.043), early-onset MG (EOMG) (HR, 1.74; <jats:italic>p<\/jats:italic> = 0.034), and ocular MG (OMG) (HR, 1.90; <jats:italic>p<\/jats:italic> = 0.007) were associated with MM status or better. In conclusion, early mono-GC, EOMG, and OMG were positive predictors of treatment goals. In EOMG, OMG, and acetylcholine receptor antibody-positive MG (AChR-MG) subgroups, the maintenance oral GC doses in the early mono-GC group were significantly lower than the doses in the delayed mono-GC group (<jats:italic>p<\/jats:italic> &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Early intervention with GC led to better long-term outcomes and reduced the necessary maintenance dose of oral GC for patients with MG. EOMG and OMG were positive predictors of MM status or better with mono-GC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1259484","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T08:39:32Z","timestamp":1702975172000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Lulu","family":"Zhen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haodong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanlian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinzheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.5692\/clinicalneurol.54.947","article-title":"Myasthenia gravis: past, present and future","volume":"54","author":"Murai","year":"2014","journal-title":"Clin. Neurol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"CD002828","DOI":"10.1002\/14651858.CD002828.pub2","article-title":"Corticosteroids for myasthenia gravis","volume":"2005","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000116785","article-title":"Long-term results of corticosteroid therapy in patients with myasthenia gravis","volume":"32","author":"Evoli","year":"1992","journal-title":"Eur Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/mus.26172","article-title":"Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies","volume":"58","author":"Europa","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J Neurol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists' management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3949\/ccjm.90a.22022","article-title":"What are the treatment options for myasthenia gravis if first-line agents fail?","volume":"90","author":"Zust","year":"2023","journal-title":"Cleve Clin J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e933296","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis","volume":"27","author":"Johnson","year":"2021","journal-title":"Med Sci Monit"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J Clin Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","article-title":"Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis","volume":"396","author":"Kanai","year":"2019","journal-title":"J Neurol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/mus.21555","article-title":"Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis","volume":"41","author":"Allen","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","article-title":"Generalization after ocular onset in myasthenia gravis: a case series in Germany","volume":"265","author":"Li","year":"2018","journal-title":"J Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/WNL.0000000000012604","article-title":"Patient-reported symptom severity in a Nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study","volume":"97","author":"Petersson","year":"2021","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"577076","DOI":"10.1016\/j.jneuroim.2019.577076","article-title":"A novel MuSK cell-based myasthenia gravis diagnostic assay","volume":"337","author":"Han","year":"2019","journal-title":"J Neuroimmunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis","volume":"26","author":"Li","year":"2019","journal-title":"Eur J Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/wnl.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1600-0404.1991.tb04899.x","article-title":"Effectiveness of steroid treatment in myasthenia gravis: a retrospective study","volume":"84","author":"Cosi","year":"1991","journal-title":"Acta Neurol Scand"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/wnl.34.2.170","article-title":"Myasthenia gravis: prolonged treatment with steroids","volume":"34","author":"Sghirlanzoni","year":"1984","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s13311-022-01335-3","article-title":"Impact of early treatment with intravenous high-dose methylprednisolone for ocular myasthenia gravis","volume":"20","author":"Uzawa","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mus.24438","article-title":"Oral corticosteroid therapy and present disease status in myasthenia gravis","volume":"51","author":"Imai","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/cns.13110","article-title":"Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: a network meta-analysis","volume":"25","author":"Wang","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"ref34","first-page":"1","article-title":"Chinese guidelines for the diagnosis and treatment of myasthenia gravis","volume":"28","author":"Ting","year":"2021","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of juvenile myasthenia gravis","volume":"11","author":"O'Connell","year":"2020","journal-title":"Front Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42466-020-00091-z","article-title":"Outcome measures and treatment effectiveness in late onset myasthenia gravis","volume":"2","author":"Pasqualin","year":"2020","journal-title":"Neurol. Res. Pract."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/wnl.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/wco.0000000000000136","article-title":"Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis","volume":"27","author":"Reddel","year":"2014","journal-title":"Curr Opin Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","article-title":"Titin antibodies in \"seronegative\" myasthenia gravis--a new role for an old antigen","volume":"292","author":"Stergiou","year":"2016","journal-title":"J Neuroimmunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1259484\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T08:39:42Z","timestamp":1702975182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1259484\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":42,"alternative-id":["10.3389\/fneur.2023.1259484"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1259484","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"article-number":"1259484"}}